ARDT · Ardent Health, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. Ardent reaffirmed full-year 2026 adjusted EBITDA guidance of $485–$535M despite softer Q2 volumes, citing $25M of volume headwinds fully offset by $20–$30M from a raised IMPACT savings target (now at least $70M, up from $55M) and a payer contract renewal expected to add $5–$10M. Q2 adjusted EBITDA fell 32.3% YoY to $115M on a 2.9% decline in total surgeries, while operating cash flow jumped 67% to $197M.
- + Raised 2026 IMPACT savings target to at least $70M from $55M, including $15–$20M from workforce restructuring
- + Payer contract renewal in one market expected to add $5–$10M to 2026 adjusted EBITDA not in prior guidance
- − Q2 adjusted EBITDA declined 32.3% YoY to $115M
- − $25M volume headwind in Q2 and H2 from softer-than-expected surgeries and admissions
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARDT
this stock
Ardent Health, Inc.
|
$1.52B | +21.7% | +6.0% | 19.5 | 2.9% |
|
HCA
HCA Healthcare, Inc.
|
$90.57B | -13.9% | +7.1% | 14.1 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.22B | -9.5% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.34B | +30.4% | +0.9% | 10.2 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$11.95B | -5.8% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARDT | -0.7% | -2.8% | +15.6% | -0.7% | +21.7% |
| SPY | -0.1% | -0.9% | +14.2% | -0.1% | +12.3% |
| vs SPY | -0.5% | -1.9% | +1.4% | -0.5% | +9.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.